Phagelux Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 8

Phagelux General Information

Description

Developer of bacteriophages designed to provide alternatives to antibiotics for multiple fields. The company offers anti-bacterial products across multiple fields utilizing various phage and phage-based technologies, enabling medical users to solve the bacterial problem and provide treatments to various diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 309, No. 88, Meiliang Road, Mashan Street
  • Binhu District
  • Wuxi, Jiangsu 214026
  • China
+86 151
Primary Industry
Drug Delivery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Vertical(s)
Corporate Office
  • Room 309, No. 88, Meiliang Road, Mashan Street
  • Binhu District
  • Wuxi, Jiangsu 214026
  • China
+86 151

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Phagelux Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 03-Apr-2025 Completed Generating Revenue
6. Later Stage VC 28-Jun-2024 Completed Generating Revenue
5. Later Stage VC 14-Nov-2022 Completed Generating Revenue
4. Later Stage VC (Series B) 10-Feb-2022 Completed Generating Revenue
3. Later Stage VC 06-Aug-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 09-Jun-2015 $10M $10M Completed Generating Revenue
1. Early Stage VC 06-Mar-2014 Completed Generating Revenue
To view Phagelux’s complete valuation and funding history, request access »

Phagelux Patents

Phagelux Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3299459-B1 Staphylococcus lyase and use thereof Active 18-May-2015
EP-3299459-A1 Staphylococcus lyase and use thereof Active 18-May-2015
EP-3299459-A4 Staphylococcus lyase and use thereof Active 18-May-2015
EP-3312275-A4 Broad spectrum of streptococcus lyase and use thereof Active 13-Apr-2015
EP-3312275-B1 Antibiotic chimeric lyase from streptococcus and uses thereof Active 13-Apr-2015 C12N9/88
To view Phagelux’s complete patent history, request access »

Phagelux Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Anhui Guokong Capital Asset Manager Minority
BioSciKin Corporation Minority
120 Capital Venture Capital Minority
Moom Capital Venture Capital Minority
Wuxi Capital Government Minority
You’re viewing 5 of 8 investors. Get the full list »

Phagelux Investments & Acquisitions (4)

Phagelux’s most recent deal was a Later Stage VC with NexaBiome for . The deal was made on 15-Mar-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
NexaBiome 15-Mar-2021 Later Stage VC Biotechnology
Scithera Microbial Technologies 14-Oct-2015 Merger/Acquisition Biotechnology
OmniLytics (Multi-line Chemicals) 20-Jul-2015 Merger/Acquisition Multi-line Chemicals
Iveria Technologies (Novel Delivery Systems) 23-Dec-2014 Merger/Acquisition Drug Delivery
To view Phagelux’s complete investments and acquisitions history, request access »

Phagelux Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
OmniLytics (Multi-line Chemicals) Sandy, UT 1954

Phagelux FAQs

  • When was Phagelux founded?

    Phagelux was founded in 2014.

  • Where is Phagelux headquartered?

    Phagelux is headquartered in Wuxi, China.

  • What industry is Phagelux in?

    Phagelux’s primary industry is Drug Delivery.

  • Is Phagelux a private or public company?

    Phagelux is a Private company.

  • What is Phagelux’s current revenue?

    The current revenue for Phagelux is .

  • How much funding has Phagelux raised over time?

    Phagelux has raised $10M.

  • Who are Phagelux’s investors?

    Anhui Guokong Capital, BioSciKin, 120 Capital, Moom Capital, and Wuxi Capital are 5 of 8 investors who have invested in Phagelux.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »